archive-ee.com » EE » Z » ZENTIVA.EE

Total: 167

Choose link from "Titles, links and description words view":

Or switch to "Titles and links view".
  • Tootekataloog - Zentiva Eesti
    skupiny Kuva tooted mille nimi algab A B C D E F G H CH I J K L M N O P Q R S T U V W X Y Z Kahjuks ei vasta ükski toode päringu kriteeriumitele Zentiva müügiluba omavate ravimite ravimiinfod saadaval Ravimiameti kodulehel www ravimiamet ee Tootekataloog Viimane uuendus 15 04 2015 19 19 Navigace Avaleht Meie kohta Meie tooted Tööpakkumised Pressikeskus Kontakt Meie tooted

    Original URL path: http://www.zentiva.ee/our-products/pages/products-search.aspx?a=l&l=X (2015-10-17)
    Open archived version from archive


  • Tootekataloog - Zentiva Eesti
    indikační skupiny Kuva tooted mille nimi algab A B C D E F G H CH I J K L M N O P Q R S T U V W X Y Z Tulemused põhinevad otsingukriteeriumitel Lehekülg 1 Zentiva müügiluba omavate ravimite ravimiinfod saadaval Ravimiameti kodulehel www ravimiamet ee Tootekataloog Viimane uuendus 15 04 2015 19 19 Navigace Avaleht Meie kohta Meie tooted Tööpakkumised Pressikeskus Kontakt Meie tooted Meie

    Original URL path: http://www.zentiva.ee/our-products/pages/products-search.aspx?a=l&l=Y (2015-10-17)
    Open archived version from archive

  • Tootekataloog - Zentiva Eesti
    B C D E F G H CH I J K L M N O P Q R S T U V W X Y Z Tulemused põhinevad otsingukriteeriumitel Zipion ZIPION 15 mg A10BG03 PIOGLITASOON ZIPION 30 mg A10BG03 PIOGLITASOON ZIPION 45 mg A10BG03 PIOGLITASOON Lehekülg 1 Zentiva müügiluba omavate ravimite ravimiinfod saadaval Ravimiameti kodulehel www ravimiamet ee Tootekataloog Viimane uuendus 15 04 2015 19 19 Navigace Avaleht Meie kohta

    Original URL path: http://www.zentiva.ee/our-products/pages/products-search.aspx?a=l&l=Z (2015-10-17)
    Open archived version from archive

  • Pildid: Zentiva - Zentiva Eesti
    Jérôme Silvestre zip fail 666 kB Zentiva Headquarters zip fail 32 2 MB Viimane uuendus 15 11 2011 13 16 Galerii Lehekülg 1 Navigace Avaleht Meie kohta Meie tooted Tööpakkumised Pressikeskus Kontakt Pressikeskus Allalaadimised Voldik Zentiva lühiülevaade Slaidikogum Pildid Zentiva Pressiteadete jaotis Kontaktandmed K obsahu Valige riik Eesti Zentiva rahvusvaheline koduleht Albaania Bulgaaria Itaalia Kazakhstan Küpros Leedu Läti Moldavia Poola Portugal Prantsusmaa Rumeenia Saksamaa Slovakkia Sloveenia Suurbritannia Šveits Tšehhi Türgi

    Original URL path: http://www.zentiva.ee/media-centre/downloads/Pages/image-library.aspx?PGPage=1 (2015-10-17)
    Open archived version from archive

  • Press release detail - Zentiva Eesti
    its clear association with modern high quality generic medicines Zentiva also has a very positive reputation in terms of providing a high level of support and service to its key customers an important success factor in the generics business By adopting a single brand the Group s European generics business Zentiva will be able to present a consistent and high quality image across all of its target markets As a result the business has become more visible and attractive to customers business partners and to potential employees The new Zentiva business will supply a growing range of generic medicines to the primary care and hospital markets across Europe Zentiva s large attractive and constantly expanding product portfolio includes over 350 medicines in important therapeutic areas such as cardiovascular gastro intestinal urology female health anti infectives pain and CNS Over the next several years Zentiva will be able to capitalise on its scale to invest in introducing a range of new and improved generic medicines designed to meet the evolving needs of patients Zentiva is led by an experienced senior management team headed by the president of Zentiva Rob Koremans and supported by strong local management in each market who have together shown the flexibility to succeed in the fast moving generics market Rob Koremans President of Zentiva commented Sanofi aventis has signaled its commitment to the Group s European Generics Business by re branding it under the name Zentiva With its pan European reach and scale Zentiva is ideally positioned to meet the ever changing demands of patients and payers across the region for better and more cost effective medicines We intend to build upon Zentiva s leading market position in European generics based on our growing product line up our talented people and our focus on patients needs About

    Original URL path: http://www.zentiva.ee/media-centre/downloads/press-releases/pages/press-release-detail.aspx?ItemId=6 (2015-10-17)
    Open archived version from archive

  • Press release detail - Zentiva Eesti
    an innovative patient friendly multi dose dry powder inhaler which is simple to use by asthmatic patients Its robust design provides excellent performance and has the ability to deliver a range of inhalation drugs The acquisition also gives Zentiva a pipeline of new generic respiratory medicines to develop The most advanced of these is a combination product containing the long acting beta agonist salmeterol and the inhaled steroid fluticasone The second is another combination product containing the long acting beta agonist formoterol and the inhaled steroid budesonide The PulmoJet device together with these combination products will enable Zentiva to enter the market for inhaled medicines used to treat asthma and chronic obstructive pulmonary disease COPD In 2009 branded products containing long acting beta agonists and steroids achieved sales of over 2 9 billion in Europe Zentiva s growth strategy is focused on expanding the range of affordable medicines to patients across Europe Its planned entry into the respiratory market is another important step in the successful execution of this strategy Rob Koremans the CEO of Zentiva commenting on today s news said Today s acquisition provides a real boost to our plans to extend the range of modern high quality affordable medicines to patients By acquiring the Siegfried Inhaler Franchise we believe we will have a strong competitive position which will allow us to become a leader in affordable respiratory medicines in the future ABOUT SANOFI AVENTIS Sanofi aventis a leading global pharmaceutical company discovers develops and distributes therapeutic solutions to improve the lives of everyone Sanofi aventis is listed in Paris EURONEXT SAN and in New York NYSE SNY ABOUT ZENTIVA Zentiva part of the sanofi aventis Group is a leading provider of modern high quality affordable medicines in Central and Eastern Europe Zentiva is headquartered in Prague Czech

    Original URL path: http://www.zentiva.ee/media-centre/downloads/press-releases/pages/press-release-detail.aspx?ItemId=3 (2015-10-17)
    Open archived version from archive

  • Press release detail - Zentiva Eesti
    Zentiva who joined sanofi aventis in September 2009 Rob has worked closely with Jiri during the last nine months to ensure a smooth and stable transition of responsibilities Based in Prague Rob Koremans reports to Hanspeter Spek President Global Operations sanofi aventis Jiri s contribution throughout his tenure at Zentiva was exceptional and I am really grateful for his achievements declared Hanspeter Spek President Global Operations sanofi aventis Zentiva is today a European leader in generics and Rob is ideally suited to lead the company to further successes Rob has an excellent track record and I am convinced that under his leadership Zentiva will consolidate its pivotal role within our European Generics Platform and deliver sustainable performance Aged 47 Rob Koremans holds a Medical degree from the Erasmus University of Rotterdam Netherlands He started his career in 1988 at Sanofi BV the Dutch subsidiary of Sanofi SA He later on joined the Serono Group in 1993 and was appointed Vice President Europe in 1998 before joining Gruenenthal in 2000 where he was appointed Member of the Executive Board between 2003 and 2007 From 2007 to 2009 Rob was Chief Executive Officer of Cryo Save Europe s leading stem cell storage

    Original URL path: http://www.zentiva.ee/media-centre/downloads/press-releases/pages/press-release-detail.aspx?ItemId=2 (2015-10-17)
    Open archived version from archive

  • Press release detail - Zentiva Eesti
    former Zentiva N V shareholder should take in connection with the reimbursement process is to contact its broker that was involved in the purchase of such shareholder s shares in Zentiva N V The broker will be able to provide necessary identification details related to the shareholder and its purchase of Zentiva N V shares This information is needed before any claim for reimbursement can be processed It is recommended that each former shareholder contacts its broker as soon as possible The broker should then contact the Central Securities Depository in Prague Centrální depozitář cenných papírů a s which is managing the reimbursements that are being made by the Dutch Consignment Office If however the former Zentiva N V shares were obtained as part of an inheritance the shareholder will have to present the relevant inheritance related documents issued by the public notary such as the will with the legal validity clause Once the shareholder or its broker has provided the Central Securities Depositary in Prague with the information needed to support the reimbursement claim it should take about two months for the reimbursement to be processed and the relevant funds to be credited to the relevant account of the shareholder Specific details of the above steps need to be discussed with the broker IMPORTANT NOTICES This document is published in English and Czech version however only its English version should be considered the official one Czech version is published solely for information purposes and no representation is made and no warranty is given as to the accuracy of the Czech tranlation Should there be any difference between the English and Czech version of this document the English version shall always prevail NOTE FOR EDITORS Zentiva part of the sanofi aventis Group is a leading provider of modern high quality

    Original URL path: http://www.zentiva.ee/media-centre/downloads/press-releases/pages/press-release-detail.aspx?ItemId=4 (2015-10-17)
    Open archived version from archive



  •